Revolution Medicines, Inc. $RVMD Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC boosted its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD) by 56.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,723 shares of the company’s stock after acquiring an additional 6,009 shares during the quarter. SG Americas Securities LLC’s holdings in Revolution Medicines were worth $1,332,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. GAMMA Investing LLC increased its position in Revolution Medicines by 45.1% in the 3rd quarter. GAMMA Investing LLC now owns 837 shares of the company’s stock valued at $39,000 after acquiring an additional 260 shares during the period. Public Employees Retirement System of Ohio increased its position in Revolution Medicines by 0.6% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 54,143 shares of the company’s stock valued at $2,528,000 after acquiring an additional 336 shares during the period. California State Teachers Retirement System increased its position in Revolution Medicines by 0.3% in the 2nd quarter. California State Teachers Retirement System now owns 140,077 shares of the company’s stock valued at $5,153,000 after acquiring an additional 437 shares during the period. Arizona State Retirement System increased its position in Revolution Medicines by 1.6% in the 3rd quarter. Arizona State Retirement System now owns 41,299 shares of the company’s stock valued at $1,929,000 after acquiring an additional 646 shares during the period. Finally, Avanza Fonder AB increased its position in Revolution Medicines by 17.5% in the 3rd quarter. Avanza Fonder AB now owns 4,335 shares of the company’s stock valued at $202,000 after acquiring an additional 647 shares during the period. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently commented on RVMD. Evercore upgraded Revolution Medicines to a “strong-buy” rating in a research report on Wednesday, February 25th. Wedbush reaffirmed an “outperform” rating on shares of Revolution Medicines in a research note on Friday, January 9th. Truist Financial raised Revolution Medicines to a “strong-buy” rating in a research note on Wednesday, March 25th. UBS Group assumed coverage on Revolution Medicines in a research note on Friday, February 27th. They set a “buy” rating for the company. Finally, Benchmark reaffirmed an “overweight” rating on shares of Revolution Medicines in a research note on Tuesday, February 17th. Five research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $78.94.

Revolution Medicines Stock Performance

RVMD opened at $96.29 on Wednesday. The firm has a market cap of $19.08 billion, a PE ratio of -16.29 and a beta of 1.01. The company has a quick ratio of 7.14, a current ratio of 7.14 and a debt-to-equity ratio of 0.16. The business has a fifty day simple moving average of $98.18 and a 200-day simple moving average of $81.78. Revolution Medicines, Inc. has a fifty-two week low of $29.98 and a fifty-two week high of $124.49.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($1.86) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.30). During the same period last year, the company earned ($1.12) earnings per share. As a group, equities analysts predict that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

Insider Buying and Selling at Revolution Medicines

In other news, COO Margaret A. Horn sold 4,583 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total transaction of $455,916.84. Following the completion of the sale, the chief operating officer directly owned 157,570 shares of the company’s stock, valued at $15,675,063.60. This trade represents a 2.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Jack Anders sold 2,753 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total value of $273,868.44. Following the sale, the chief financial officer directly owned 125,512 shares of the company’s stock, valued at approximately $12,485,933.76. This represents a 2.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 64,592 shares of company stock worth $6,488,732. 8.20% of the stock is owned by insiders.

Revolution Medicines Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.